IP Library Granted Patent US 11,377,655
Granted Patent B2
US 11,377,655 · App. 16/931,200 · Granted Jul 5, 2022

Synthetic nucleic acids having non-natural structures

Inventors: Arnold Oliphant (San Diego, CA); James Yu (San Diego, CA)
Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
C12N15/1096C12N15/111C40B40/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,377,655
App. No.
16/931,200
Granted
Jul 5, 2022
Kind
B2
Abstract

Nucleic acid compositions having nucleotide sequences that do not occur in nature are provided. Also provided are populations of different nucleic acids having universal adapters or universal primer binding sites. Methods of capturing, copying or amplifying nucleic acids of interest using universal adapters, universal primer binding sites and/or universal primers are also provided.

Claims (31)

1. A composition comprising an isolated nucleic acid molecule comprising the sequence or the complement of SEQ ID NO:1.

2. The composition of claim 1 , wherein the 3′ end of the sequence of SEQ ID NO:1 is the 3′ end of a strand of the isolated nucleic acid molecule, or wherein the 3′ end of the complement of SEQ ID NO:1 is the 3′ end of a strand of the isolated nucleic acid molecule.

3. The composition of claim 1 , wherein the isolated nucleic acid molecule is single stranded.

4. The composition of claim 1 , wherein the isolated nucleic acid molecule is double stranded, thereby having a first strand and a second strand.

5. The composition of claim 4 , wherein the first strand of the isolated nucleic acid molecule comprises the sequence of SEQ ID NO:1 and wherein the second strand of the isolated nucleic acid comprises the complement of SEQ ID NO:1.

6. The composition of claim 1 , wherein the nucleic acid comprises DNA.

7. The composition of claim 1 , wherein the nucleic acid comprises RNA.

8. The composition of claim 1 , wherein the nucleic acid comprises a linker moiety, the linker moiety being exogenous to the nucleic acid.

9. The composition of claim 8 , wherein the linker moiety attaches the nucleic acid to a label moiety, the label moiety being exogenous to the nucleic acid.

10. The composition of claim 8 , wherein the exogenous linker moiety attaches the nucleic acid to a solid phase support.

11. The composition of claim 10 , wherein the solid phase support comprises a bead.

12. The composition of claim 10 , wherein the solid phase support comprises a site of a nucleic acid array.

13. The composition of claim 1 , wherein the nucleic acid molecule is in solution phase.

14. The composition of claim 1 , wherein the isolated nucleic acid molecule further comprises the sequence or the complement of SEQ ID NO:3.

15. The composition of claim 14 , wherein the 3′ end of the sequence of SEQ ID NO:3 is the 3′ end of a strand of the isolated nucleic acid molecule, or wherein the 3′ end of the complement of SEQ ID NO:3 is the 3′ end of a strand of the isolated nucleic acid molecule.

16. The composition of claim 14 , wherein the isolated nucleic acid molecule is double stranded, thereby having a first strand and a second strand.

17. The composition of claim 16 , wherein the first strand of the isolated nucleic acid molecule comprises the sequence of SEQ ID NO:3 and wherein the second strand of the isolated nucleic acid comprises the complement of SEQ ID NO:3.

18. The composition of claim 17 , wherein the first strand of each of the nucleic acid molecules comprises the sequence of SEQ ID NO:1 and wherein the second strand of each of the nucleic acid molecules comprises the complement of SEQ ID NO:1.

19. The composition of claim 17 , wherein the first strand of each of the nucleic acid molecules comprises the complement of SEQ ID NO:1 and wherein the second strand of each of the nucleic acid molecules comprises the sequence of SEQ ID NO:1.

20. The composition of claim 1 , wherein the isolated nucleic acid molecule further comprises a variant of SEQ ID NO:3 having 1, 2, 3 or 4 nucleotide substitutions.

21. The composition of claim 20 , wherein the variant is SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

22. A population of different nucleic acid molecules, comprising a plurality of nucleic acid molecules,

wherein each of the nucleic acid molecules comprises a universal sequence region and a variable sequence region,

wherein the sequence of the variable sequence region differs between different nucleic acid molecules in the population,

wherein the sequence of the universal sequence region is the same for the nucleic acid molecules in the population, and

wherein the universal sequence region comprises the sequence or the complement of SEQ ID NO:1.

23. A method for preparing a nucleic acid library, comprising

attaching universal adapters to nucleic acid fragments from a genome, thereby producing a library of nucleic acid molecules,

wherein each of the nucleic acid molecules in the library comprises:

(i) a variable sequence region that differs between the nucleic acid molecules in the library, and

(ii) a universal sequence region that is the same for the nucleic acid molecules in the library, wherein the universal sequence region comprises the sequence or the complement of SEQ ID NO:1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: OMNIOME, LLC
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 059278/0153 →
MERGER Recorded Feb 2, 2022
From: OMNIOME, INC.
To: OMNIOME, LLC
Reel/Frame 058952/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2021
From: OLIPHANT, ARNOLD
To: OMNIOME, INC.
Reel/Frame 055591/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: YU, JAMES
To: OMNIOME, INC.
Reel/Frame 053233/0151 →
Continuity (2)
Provisional Application 62874601 · Jul 16, 2019
Related Publication 20210017517A1 · Jan 21, 2021